Shuwen Develops Companion Diagnostics for BlissBio in New Collaboration

Shuwen Biotech of Deqing will partner with Bliss Biopharma, a one-year-old Hangzhou company, to develop companion diagnostics for BlissBio’s oncology drug candidates. Shuwen will also provide testing services in its CAP-certified central labs for BlissBio clinical trials. Two months ago, BlissBio in-licensed exclusive rights to an antibody drug conjugate technology for a cancer target from Morphotek, a US subsidiary of Japan's Eisai (TYO: 4523). More details....

Share this with colleagues:

Original Article: Shuwen Develops Companion Diagnostics for BlissBio in New Collaboration

More From BioPortfolio on "Shuwen Develops Companion Diagnostics for BlissBio in New Collaboration"